New inhaled therapy aims to ease strain on scarred lungs
NCT ID NCT07333183
Summary
This study is testing the safety of a new inhaled drug, mosliciguat, when added to an existing inhaled medication (treprostinil) for people with pulmonary hypertension caused by scarred lungs (interstitial lung disease). The goal is to see if the two-drug combination is safe and helps control the disease. About 20 participants will take the new drug for 16 weeks, with an option to continue longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Florida Lung, Asthma & Sleep Specialists/Clinical Research Specialists, LLC
RECRUITINGKissimmee, Florida, 34746, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.